Abstract
Serum S-100 protein is widely used as a marker of melanoma and since 5-S-cysteinyldopa (5-S-CD) is a precursor of melanin its serum and urinary levels can reflect melanoma progression. In this study we examined the concentration changes of serum S-100 protein and 5-S-CD in 252 melanoma patients of different clinical stages. Serum samples were taken from 252 melanoma patients at 860 times, from June 1996 to July 1998. The serum S-100 protein was measured by the immunoluminometric assay, levels of 5-S-CD was determined by HPLC The value of S-100 protein in patients with primary melanoma (0.11 μg/1) and in patients without symptoms (0.15 μg/1) ranged around the normal level (0.01–0.12 μg/1). There was a significant difference between the values of patients with or without symptoms. There was a similarly significant difference between the S-100 values of clinical Stage I (0.11 μg/l) and Stage III (2.91 μg/l) as well as between those of clinical Stage II (0.47 μg/l) and Stage III (2.91 μg/l) respectively Analyzing the values of patients with symptoms we observed significant difference between the S-100 protein values of patients with primary tumor and those with solitary or multiple distant metastases. In case of 5-S-CD significant difference was found between clinical Stage I and III as well as clinical Stage II and III. Furthermore, there was a significant difference between the mean marker values of patients with primary tumor, lymph node, lung metastasis and clinical stage III.
Similar content being viewed by others
References
Agrup G, Agrup P, Andersson T, et al: 5 years experience of 5-S-cysteinyldopa in melanoma diagnosis. Acta Dermatovener (Stockholm) 59:381–388, 1979.
Benathan M: Modulation of 5-S-cysteinyldopa formation by tyrosinase activity and intracellular thiols in human melanoma cells. Melanoma Res 6:183–189, 1996.
Bonfrer JM, Korse CM, Israels SP: Serum S-100 has prognostic significance in malignant melanoma. Anticancer Res 17:2975–7, 1997.
Buer J, Probst M, Franzke A, et al: Elevated serum levels of S-100 and survival in metastatic malignant melanoma. Br J Cancer 75:1373–6, 1997.
Cho K, Hashimoto K, Taniguchi Y, et al: Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunit. Cancer 66:765–771, 1990.
Fagnart CO, Sindic MJ, Laterre CH: Particle counting immunassay of S-100 protein in serum. Possible relevance in tumours and ischemic disorders of the central nervous system. Clin Chem 34:1387–1391, 1988.
Gaynor R, Irie R, Morton D: S-100 protein is present in cultured human malignant melanomas:. Nature 286:400–401,1980.
Gaynor R, Irie R, Morton D, et al: S-100 protein: A marker for human malignant melanoma? Lancet 18:869–871, 1981.
Guo HB.Stoffel-Wagner B, Bierwirth T, et al: Clinical significance of serum S-100 in metastatic malignant melanoma. Eur J Cancer 31:1898–1902, 1995.
Hanson LO, Schoultz E, Djuren E, et al: Prognostic value of serum analyses of S-100 protein beta in malignant melanoma. Anticancer Res 17:3071–3073, 1997.
Hasegawa M, Takata M, Hatta N, et al: Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma Melanoma Res 7:243–251, 1997.
Henze G, Dummer R, Joller-Jemelka H, et al: Serum S-100 - a marker for disease monitoring in metastatic melanoma. Dermatology 194:208–212, 1997.
Hirai S, Kageshita T, Kimura T, et al: Serum levels of s-ICAM, and 5-S-cysteinyldopa as: markers of melanoma progression. Melanoma Res 7:58–62, 1997.
Horikoshi T, Ito Sh, Wakamatsu K, et al: Evaluation of melaninrelated metabolites as markers of melanoma progression. Cancer 73:629–636, 1994.
Kagedal B, Pettersson A: Determination of urinary 5-S-cysteinyldopa by high performance liqiud chromatography Chromatogr 272:287–297, 1983.
Ketcham AS, Moffat FL, Balch CM: Classification and staging In: CM Balch Cutaneous melanoma Philadelphia, JB Lippincott, 1992, pp. 213–220.
Meyerhoffer S, Lindberg Z, Hager A, et al: Urinary excretion of 5-S-cysteinyldopa and 6-hydroxy-5-methoxymdole-2-carboxylic acid in children Acta Derm Venereol 78:31–35, 1998.
Miliotes G, Lyman GH, Cruse CW, et al: Evalutaiton of new putative tumor markers for melanoma Ann Surg Oncol 3:558–563, 1996.
Nakajima T, Watanabe S, Sato Y, et al: Immunohistochemical demonstration of S-100 protein in malignant melanoma and pigmented nevus and its diagnostic application. Cancer 50:912–918, 1982.
Nyberg L, Kroon L, Ullen A, et al: Sangtee LIA a new sensitive monoclonal assay for measuring protein S 100 in patients with malignant melanoma in Final Program and Abstract Book of the XXIV Meeting of ISOBM. San Diego, 1996.
Peterson L, Woodward W, Fletcher W, et al: Plasma 5-S-cysteinyldopa differentietes patients with primary and metastatic melanoma from patients with dyspiasticus naevus syndroma and normal subjects. J Am Acad Dermatol 19:509–515, 1988
Schoultz E, Hansson LO, Djureen E, et al: Prognostic value of serum analyses of S-100 beta protein in malignant melanoma. Melanoma Res 6:133–137, 1996.
Schoultz ES, Diepgen TL, Von Den DrieschP: Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma Br J Dermatol 138:426–430, 1998.
Sasaki Y, Shimizu H, Naka W et al: Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: ten years experience of 50 patients Acta Derm Venerol 77:379–381, 1998.
Wakamatsu K, Ito S: Seasonal variations in serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxyI acid in healthy Japanese. Pigment Cell Res 8:132–134, 1995.
Wimmer I, Meyer CJ, Seifert B, et al.: Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemoterapy. Cancer Res 57:5073–5076, 1997.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
BÁnfalvi, T., Gilde, K., BoldizsÁr, M. et al. Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression. Pathol. Oncol. Res. 5, 218–222 (1999). https://doi.org/10.1053/paor.1999.0218
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1053/paor.1999.0218